Actuate Therapeutics (ACTU) Competitors $6.56 -0.19 (-2.74%) As of 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ACTU vs. UPB, SAGE, ALT, TNGX, KROS, RLAY, AUTL, ARVN, DNTH, and MNMDShould you be buying Actuate Therapeutics stock or one of its competitors? The main competitors of Actuate Therapeutics include Upstream Bio (UPB), Sage Therapeutics (SAGE), Altimmune (ALT), Tango Therapeutics (TNGX), Keros Therapeutics (KROS), Relay Therapeutics (RLAY), Autolus Therapeutics (AUTL), Arvinas (ARVN), Dianthus Therapeutics (DNTH), and Mind Medicine (MindMed) (MNMD). These companies are all part of the "pharmaceutical products" industry. Actuate Therapeutics vs. Its Competitors Upstream Bio Sage Therapeutics Altimmune Tango Therapeutics Keros Therapeutics Relay Therapeutics Autolus Therapeutics Arvinas Dianthus Therapeutics Mind Medicine (MindMed) Upstream Bio (NASDAQ:UPB) and Actuate Therapeutics (NASDAQ:ACTU) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings. Does the media prefer UPB or ACTU? In the previous week, Actuate Therapeutics had 8 more articles in the media than Upstream Bio. MarketBeat recorded 9 mentions for Actuate Therapeutics and 1 mentions for Upstream Bio. Actuate Therapeutics' average media sentiment score of 1.34 beat Upstream Bio's score of 0.93 indicating that Actuate Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Upstream Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Actuate Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate UPB or ACTU? Upstream Bio currently has a consensus price target of $56.50, suggesting a potential upside of 404.24%. Actuate Therapeutics has a consensus price target of $20.50, suggesting a potential upside of 212.74%. Given Upstream Bio's higher possible upside, equities analysts plainly believe Upstream Bio is more favorable than Actuate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Upstream Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Actuate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is UPB or ACTU more profitable? Company Net Margins Return on Equity Return on Assets Upstream BioN/A N/A N/A Actuate Therapeutics N/A N/A -339.73% Which has preferable earnings and valuation, UPB or ACTU? Actuate Therapeutics has lower revenue, but higher earnings than Upstream Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUpstream Bio$2.37M254.31-$62.81MN/AN/AActuate TherapeuticsN/AN/A-$27.28MN/AN/A SummaryUpstream Bio beats Actuate Therapeutics on 4 of the 7 factors compared between the two stocks. Get Actuate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACTU and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACTU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACTU vs. The Competition Export to ExcelMetricActuate TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$128.61M$2.90B$5.50B$9.01BDividend YieldN/A2.64%5.39%4.11%P/E RatioN/A21.5027.4220.07Price / SalesN/A282.64398.50109.13Price / CashN/A41.4736.1356.90Price / Book655.507.518.015.70Net Income-$27.28M-$55.05M$3.16B$248.47M7 Day Performance12.63%3.05%2.08%2.92%1 Month Performance-32.77%5.80%4.38%5.77%1 Year PerformanceN/A6.15%35.81%21.39% Actuate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACTUActuate Therapeutics2.9372 of 5 stars$6.56-2.7%$20.50+212.7%N/A$128.61MN/A0.0010Positive NewsInsider TradeUPBUpstream Bio1.8817 of 5 stars$10.72-1.5%$56.50+427.1%N/A$585.28M$2.37M0.0038SAGESage Therapeutics3.2373 of 5 stars$9.30flat$8.93-3.9%-16.1%$582.37M$41.24M-1.60690ALTAltimmune2.3093 of 5 stars$6.99-0.6%$19.00+171.8%-27.3%$570.18M$20K-5.5550TNGXTango Therapeutics2.3097 of 5 stars$5.32+3.1%$12.20+129.3%-30.2%$559.31M$42.07M-4.3690Analyst RevisionKROSKeros Therapeutics4.1572 of 5 stars$13.76+2.0%$30.56+122.1%-68.7%$547.90M$3.55M-76.44100Positive NewsRLAYRelay Therapeutics3.0754 of 5 stars$3.23+1.3%$17.67+447.0%-44.4%$546.91M$10.01M-1.45330AUTLAutolus Therapeutics2.725 of 5 stars$2.21+7.8%$9.32+321.7%-30.5%$545.59M$10.12M-2.51330Positive NewsARVNArvinas3.7379 of 5 stars$7.40-0.5%$20.29+174.2%-68.2%$543.06M$263.40M-11.21420Positive NewsDNTHDianthus Therapeutics1.4623 of 5 stars$17.20+2.1%$53.00+208.1%-30.0%$542.06M$6.24M-5.9780News CoverageAnalyst ForecastMNMDMind Medicine (MindMed)2.6372 of 5 stars$6.64-5.8%$25.50+284.0%+1.7%$532.65MN/A-5.1540 Related Companies and Tools Related Companies UPB Competitors SAGE Competitors ALT Competitors TNGX Competitors KROS Competitors RLAY Competitors AUTL Competitors ARVN Competitors DNTH Competitors MNMD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACTU) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actuate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Actuate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
